Overview

Clinical Study to Evaluate the Safety and Tolerability of Macitentan in Subjects With Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH) Due to Left Ventricular Dysfunction

Status:
Completed

Trial end date:
2015-11-01

Target enrollment:

Participant gender:

Summary

Study to evaluate if macitentan is safe and tolerable enough to be used for treatment of subjects with combined pre- and post-capillary pulmonary hypertension (CpcPH) due to left ventricular dysfunction.

Phase:

Phase 2

Details

Lead Sponsor:

Actelion

Treatments:

Macitentan